In many cases, these studies may have been confounded by heterogeneity in the spectrum of detected TP53 alterations as well as heterogeneity in breast cancer subtype, which impacts both frequency and type of TP53 alteration and neoadjuvant therapy response rates. This evidence concerns the gene TP53 and breast cancer.